Skip to main content

Ceftolozane / Tazobactam Dosage

Medically reviewed by Drugs.com. Last updated on Jun 18, 2024.

Applies to the following strengths: 1 g-0.5 g

Usual Adult Dose for Intraabdominal Infection

1.5 g IV every 8 hours
Duration of therapy: 4 to 14 days

Comments:


Use: In combination with metronidazole, for the treatment of complicated intraabdominal infections due to susceptible Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, S constellatus, S salivarius

Usual Adult Dose for Pyelonephritis

1.5 g IV every 8 hours
Duration of therapy: 7 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Usual Adult Dose for Urinary Tract Infection

1.5 g IV every 8 hours
Duration of therapy: 7 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Usual Adult Dose for Nosocomial Pneumonia

3 g IV every 8 hours
Duration of therapy: 8 to 14 days

Uses: For the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) due to susceptible E cloacae, E coli, Haemophilus influenzae, K oxytoca, K pneumoniae, P mirabilis, P aeruginosa, Serratia marcescens

Usual Pediatric Dose for Intraabdominal Infection

Birth to less than 18 years: 30 mg/kg IV every 8 hours
Maximum dose: 1.5 g/dose
Duration of therapy: 5 to 14 days

Comments:


Use: In combination with metronidazole, for the treatment of complicated intraabdominal infections due to susceptible E cloacae, E coli, K oxytoca, K pneumoniae, P mirabilis, P aeruginosa, B fragilis, S anginosus, S constellatus, S salivarius

Usual Pediatric Dose for Pyelonephritis

Birth to less than 18 years: 30 mg/kg IV every 8 hours
Maximum dose: 1.5 g/dose
Duration of therapy: 7 to 14 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Usual Pediatric Dose for Urinary Tract Infection

Birth to less than 18 years: 30 mg/kg IV every 8 hours
Maximum dose: 1.5 g/dose
Duration of therapy: 7 to 14 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Renal Dose Adjustments

Adult Patients:


Pediatric Patients (birth to less than 18 years):

Comments:

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS:
Known serious hypersensitivity to either active component, piperacillin-tazobactam, or other members of the beta-lactam class

Safety and efficacy have not been established in patients younger than 18 years with HABP/VABP.

Consult WARNINGS section for additional precautions.

Dialysis

Adult Patients:


Comments:

Other Comments

3 g ceftolozane-tazobactam contains 2 g ceftolozane and 1 g tazobactam
2.25 g ceftolozane-tazobactam contains 1.5 g ceftolozane and 0.75 g tazobactam
1.5 g ceftolozane-tazobactam contains 1 g ceftolozane and 0.5 g tazobactam
750 mg ceftolozane-tazobactam contains 500 mg ceftolozane and 250 mg tazobactam
450 mg ceftolozane-tazobactam contains 300 mg ceftolozane and 150 mg tazobactam
375 mg ceftolozane-tazobactam contains 250 mg ceftolozane and 125 mg tazobactam
150 mg ceftolozane-tazobactam contains 100 mg ceftolozane and 50 mg tazobactam

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.